GlassScriptPhysician profile
Arjun V Balar
NPI 1558528273
$148,926.17
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $48K · 2021: $43K · 2022: $1,028.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $74,817.93 | 2019-2021 | |
| Seagen INC. | $26,591.09 | 2019-2021 | |
| Glaxosmithkline, LLC. | $16,574.96 | 2019-2020 | |
| Genentech, INC. | $8,006.47 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $4,304.50 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $3,802.00 | 2021 | |
| Pfizer INC. | $3,647.48 | 2020 | |
| F. Hoffmann-La Roche Ag | $2,921.54 | 2019 | |
| Astellas Pharma Global Development | $2,500.00 | 2021 | |
| Janssen Research & Development, LLC | $1,620.00 | 2019 | |
| Eli Lilly and Company | $1,400.00 | 2021 | |
| Gilead Sciences, INC. | $1,400.00 | 2021 | |
| Immunomedics, INC. | $1,050.00 | 2020 | |
| Genentech USA, INC. | $257.52 | 2019-2021 | |
| Janssen Biotech, INC. | $17.10 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $15.58 | 2019 |
4 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arjun Balar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.